Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
Actos (1) ·
Allegra, Allegra Allergy 24 Hour, Mucinex Allergy (combo) — all now OTC in US (1) ·
Amaryl (1) ·
Antivert (Rx), Bonine (OTC), Dramamine Less Drowsy (OTC) (1) ·
Flexeril (IR; brand discontinued in US, generic widely available), Amrix (ER) (1) ·
Lantus, Basaglar, Semglee, Toujeo (U-300) (1) ·
Levemir, Levemir FlexTouch (US discontinuation announced 2024) (1) ·
Tresiba (1)
classes:
[[:Category:Antiemetics|Antiemetic]] (1) ·
[[:Category:Antihistamines|Antihistamine]] (1) ·
[[:Category:Antihistamines|First-generation antihistamine (piperazine)]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (2) ·
[[:Category:Antivertigo medicines|Antivertigo medicine]] (1) ·
[[:Category:Basal_insulins|Basal insulin]] (3) ·
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist (second-generation)]] (1) ·
[[:Category:Insulins|Insulin]] (3) ·
[[:Category:Insulin_secretagogues|Insulin secretagogue]] (1) ·
[[:Category:Long-acting_insulins|Long-acting insulin analog]] (2) ·
[[:Category:PPAR_gamma_agonists|PPAR-γ agonist]] (1) ·
[[:Category:Skeletal muscle relaxants|Skeletal muscle relaxant (centrally-acting)]] (1) ·
[[:Category:Sulfonylureas|Sulfonylurea (third-generation)]] (1) ·
[[:Category:Thiazolidinediones|Thiazolidinedione (TZD)]] (1) ·
[[:Category:Tricyclic-related compounds|Tricyclic-related compound]] (1) ·
[[:Category:Ultra-long-acting_insulins|Ultra-long-acting insulin analog]] (1)
mechanism:
None (4) ·
'"`UNIQ--vote-00000013-QINU`"' Anticholinergic burden (dry mouth, blurred vision, urinary retention, cognitive effects) is the principal adverse-event concern and the basis for Beers-list cautions in elderly patients'"`UNIQ--ref-00000014-QINU`"'. (1) ·
'"`UNIQ--vote-00000237-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio; provides basal hepatic glucose suppression and peripheral glucose uptake without prandial peaks'"`UNIQ--ref-00000238-QINU`"'. (1) ·
'"`UNIQ--vote-00000CC9-QINU`"' Mostly excreted unchanged in feces and urine; P-glycoprotein substrate (the basis of the fruit-juice interaction). (1) ·
'"`UNIQ--vote-00001356-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio'"`UNIQ--ref-00001357-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"', '"`UNIQ--vote-00000017-QINU`"' (1) ·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (1) ·
'"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"' (1) ·
'"`UNIQ--vote-00000491-QINU`"' (1) ·
'"`UNIQ--vote-00000822-QINU`"', '"`UNIQ--vote-00000823-QINU`"' (1) ·
'"`UNIQ--vote-00000CCA-QINU`"', '"`UNIQ--vote-00000CCB-QINU`"' (1) ·
'"`UNIQ--vote-00001358-QINU`"', '"`UNIQ--vote-00001359-QINU`"' (1) ·
'"`UNIQ--vote-00001372-QINU`"', '"`UNIQ--vote-00001373-QINU`"' (1)
starting dose:
1-2 mg PO once daily with breakfast; titrate by glycemic response (1) ·
15-30 mg PO once daily; titrate to 45 mg (1) ·
60 mg PO BID or 180 mg PO once daily (1) ·
IR 5 mg PO TID; titrate to 10 mg TID if needed. Amrix ER 15 mg PO once daily. Off-label insomnia / fibromyalgia: 5-10 mg PO at bedtime (1) ·
Motion sickness: 25-50 mg PO 1 hour before travel, repeat every 24 hours as needed. Vertigo: 25-100 mg/day divided (1) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (2) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses (1)
preparations:
1 mg, 2 mg, 4 mg tablets (1) ·
100 U/mL (FlexTouch pen) and 200 U/mL (FlexTouch pen, higher-dose convenience) (1) ·
100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens (1) ·
100 U/mL FlexTouch pen, vial (1) ·
15, 30, 45 mg tablets (1) ·
30, 60, 180 mg tablets; 30 mg ODT; 6 mg/mL oral suspension; all OTC (1) ·
IR tablets 5, 7.5, 10 mg; Amrix ER capsules 15, 30 mg (1) ·
Tablets 12.5, 25 mg; chewable tablets 25 mg (1)
fda max:
onset: (Click arrow to add another value)
duration:
12-24 hours (1) ·
12-24 hours (IR); 24 hours (Amrix ER) (1) ·
12-24 hours (long for an antihistamine) (1) ·
24 hours (2) ·
>42 hours per dose (effectively flat once at steady state) (1) ·
~12-24 hours (dose-dependent; BID dosing often needed at higher doses) (1) ·
~24 hours per dose (peakless profile by design) (1)
halflife:
18 hours (IR); 32-33 hours (ER)'"`UNIQ--ref-0000001A-QINU`"' (1) ·
~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' (1) ·
~14 hours'"`UNIQ--ref-00000CCC-QINU`"' (1) ·
~25 hours apparent (functional duration well over 42 hours from multi-hexamer depot)'"`UNIQ--ref-0000135A-QINU`"' (1) ·
~3-7 hours (parent); 16-24 hours including active metabolites'"`UNIQ--ref-00000824-QINU`"' (1) ·
~5-9 hours (parent and active metabolites combined)'"`UNIQ--ref-00000492-QINU`"' (1) ·
~6 hours'"`UNIQ--ref-00000018-QINU`"' (1) ·
~7 hours apparent'"`UNIQ--ref-00001374-QINU`"' (1)
bioavailability:
High (oral; absorption not affected by food)'"`UNIQ--ref-00000825-QINU`"' (1) ·
~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"' (1) ·
~100% from subcutaneous depot (1) ·
~100% from subcutaneous depot (by definition of the route) (1) ·
~25% (oral)'"`UNIQ--ref-00000019-QINU`"' (1) ·
~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)'"`UNIQ--ref-00000CCD-QINU`"' (1) ·
~33-55% (IR); reduced by food'"`UNIQ--ref-0000001B-QINU`"' (1) ·
~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"' (1)
pregnancy:
Avoid; switch to insulin. Neonatal hypoglycemia reported.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; loratadine and cetirizine have more pregnancy data and are typically preferred.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; degludec has reassuring observational data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Older agent with substantial use experience; observational signals reassuring for first-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
One of the better-studied basal insulin analogs in pregnancy; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
OTC in US (1) ·
[[USLegal:Over-the-counter|OTC]] as Bonine and Dramamine Less Drowsy; [[USLegal:Prescription only|Rx-only]] as Antivert (1) ·
[[USLegal:Prescription only|Rx-only]] in US (4) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for heart failure (do not initiate in NYHA III/IV; can precipitate or worsen HF in any patient)'"`UNIQ--ref-00000826-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, distinguishing it from the carisoprodol alternative for muscle spasm'"`UNIQ--ref-0000001C-QINU`"' (1)
Error: operator for the virtual field 'Medicines.classes' must be 'HOLDS', 'HOLDS NOT', 'HOLDS LIKE' or 'HOLDS NOT LIKE'.
There are no results for this report.